RHOPRESSA OPHTHALMIC SOLUTION, 0.02% W/V

PRESCRIPTION ONLY MEDICINES
Drug type: Therapeutic
ATC code: S01EX05
Dosage form: SOLUTION, STERILE
Route of administration: OPHTHALMIC
Active ingredient: Netarsudil mesylate eqv Netarsudil; NETARSUDIL MESYLATE EQV NETARSUDIL

1. INDICATIONS AND USAGE
RHOPRESSA (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension [see section 12 Clinical Studiesplease refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].

4. CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients.

2. DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.

If one dose is missed, treatment should continue with the next dose in the evening. Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.

Due to netarsudil’s vasodilating properties, other eye drops should be administered before netarsudil. Eye ointments should be administered last.

Registrant
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
Approval Date
2023-07-04
Approval Number
SIN16816P
Manufacturer
SANTEN PHARMACEUTICAL CO., LTD. SHIGA PLANT (JAPAN)
Licence Holder
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
RHOPRESSA OPHTHALMIC SOLUTION, 0.02% W/V | MedPath